CA3147314A1 - Procedes de production et d'utilisation de compositions de lipooligosaccharides et vaccins - Google Patents

Procedes de production et d'utilisation de compositions de lipooligosaccharides et vaccins Download PDF

Info

Publication number
CA3147314A1
CA3147314A1 CA3147314A CA3147314A CA3147314A1 CA 3147314 A1 CA3147314 A1 CA 3147314A1 CA 3147314 A CA3147314 A CA 3147314A CA 3147314 A CA3147314 A CA 3147314A CA 3147314 A1 CA3147314 A1 CA 3147314A1
Authority
CA
Canada
Prior art keywords
gonorrhoeae
compositions
nlc4
aluminum
los
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3147314A
Other languages
English (en)
Inventor
J. McLeod GRIFFISS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crapaud Bio Inc
Original Assignee
Crapaud Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crapaud Bio Inc filed Critical Crapaud Bio Inc
Publication of CA3147314A1 publication Critical patent/CA3147314A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne, de manière générale, des compositions et des procédés permettant le traitement et/ou la prévention d'une infection gonococcique et/ou d'une gonorrhée chez un sujet. L'invention concerne en outre la fourniture de cellules hôtes microbiennes transformées (par exemple, des cellules bactériennes) qui ont été fabriquées pour produire des lipooligosaccharides de Neisseria modifiés et/ou d'origine non naturelle par l'intermédiaire d'une intégration stable de séquences génétiques. L'invention concerne en outre des compositions immunogènes et des vaccins qui comprennent, dans leur partie pertinente, un ou plusieurs lipooligosaccharides dérivés de N. gonorrhoeae.
CA3147314A 2019-07-08 2020-07-08 Procedes de production et d'utilisation de compositions de lipooligosaccharides et vaccins Pending CA3147314A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962871472P 2019-07-08 2019-07-08
US62/871,472 2019-07-08
US201962872973P 2019-07-11 2019-07-11
US62/872,973 2019-07-11
PCT/US2020/041272 WO2021007365A1 (fr) 2019-07-08 2020-07-08 Procédés de production et d'utilisation de compositions de lipooligosaccharides et vaccins

Publications (1)

Publication Number Publication Date
CA3147314A1 true CA3147314A1 (fr) 2021-01-14

Family

ID=74114998

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3147314A Pending CA3147314A1 (fr) 2019-07-08 2020-07-08 Procedes de production et d'utilisation de compositions de lipooligosaccharides et vaccins

Country Status (6)

Country Link
EP (1) EP3997108A4 (fr)
JP (1) JP2022541757A (fr)
AU (1) AU2020309556A1 (fr)
CA (1) CA3147314A1 (fr)
IL (1) IL289690A (fr)
WO (1) WO2021007365A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545553A (en) * 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US6610306B2 (en) * 1998-10-22 2003-08-26 The University Of Montana OMP85 protein of neisseria meningitidis, compositions containing the same and methods of use thereof
US7261901B2 (en) * 2001-01-31 2007-08-28 University Of Iowa Research Foundation Vaccine and compositions for the prevention and treatment of neisserial infections
WO2002060936A2 (fr) * 2001-01-31 2002-08-08 University Of Iowa Research Foundation Vaccin et compositions permettant de prevenir et de traiter des infections induites par neisseria
GB0819633D0 (en) * 2008-10-25 2008-12-03 Isis Innovation Composition

Also Published As

Publication number Publication date
IL289690A (en) 2022-03-01
EP3997108A1 (fr) 2022-05-18
JP2022541757A (ja) 2022-09-27
AU2020309556A1 (en) 2022-03-03
WO2021007365A1 (fr) 2021-01-14
EP3997108A4 (fr) 2024-03-20

Similar Documents

Publication Publication Date Title
US20210299239A1 (en) Novel th1-inducing adjuvant comprising combination of different nucleic acid adjuvants, and use of same
Chai et al. Host defense mechanisms against Mycobacterium tuberculosis
ES2606563T3 (es) Adyuvantes lipídicos de glucopiranosilo sintéticos y composiciones de vacuna que contienen los mismos
JP5564672B2 (ja) アジュバント及びその使用方法
EP2271661B3 (fr) Dérivés du muramylpeptide
US9241954B2 (en) Lipopolysaccharide of ochrobactrum intermedium and their use as immunostimulant of mammalians
TR201807756T4 (tr) Sentetik adjuvan içeren aşı bileşimi.
JPH11501634A (ja) 免疫系異常治療用の胆汁からの免疫調節組成物
Schwacha et al. Interleukin-12 is critical for induction of nitric oxide-mediated immunosuppression following vaccination of mice with attenuated Salmonella typhimurium
CA3147314A1 (fr) Procedes de production et d'utilisation de compositions de lipooligosaccharides et vaccins
KR101795524B1 (ko) 마이코플라즈마 감염증용 백신
WO2013050413A1 (fr) Procédés d'obtention d'une population de lymphocytes t régulateurs
US20220257752A1 (en) New use of cyclic dinucleotides
US20170298083A1 (en) New immunostimulatory compounds
Lin et al. The opposing effects of lipopolysaccharide on the antitumor therapeutic efficacy of DNA vaccine
CN108348537B (zh) 用cmp活化吡喃壬酮糖酸类似化合物治疗和预防奈瑟氏淋病球菌感染
Mierzejewska et al. De‑O‑acylated lipooligosaccharide of E. coli B reduces the number of metastatic foci via downregulation of myeloid cell activity